On the morning of November 7, the strategic cooperation signing ceremony between Nanchang Hua'an Zhonghui Health Technology Co., Ltd. and Boni Medical Technology (Changzhou) Co., Ltd. was held in Changzhou, Jiangsu Province, marking a new phase of deep integration between the two parties.

Present at the signing ceremony were Zhang Xianfeng, Director of the Chengdong Industrial Park Management Office; Zhou Mingqi, Deputy General Manager of Hutang Science and Technology Industrial Park Investment Management Company; Chen Hua, Chairman of Nanchang Hua'an Zhonghui Health Technology Co., Ltd.; and Shen Xing, Chairman and Founder of Boni Medical Technology (Changzhou) Co., Ltd.

Against the backdrop of the global wave of technological innovation in the healthcare industry, this strategic cooperation between a high-frequency electrosurgical enterprise and a minimally invasive surgical medical device company has attracted significant attention.

According to Frost & Sullivan data analysis, the scale of China's minimally invasive surgical instruments and consumables market reached RMB 26.79 billion in 2022. It is expected that this market will grow at a compound annual growth rate (CAGR) of 13.2% in the coming years, reaching RMB 38.91 billion by 2025. Looking further ahead, the market size is projected to expand to RMB 61.77 billion by 2030, with an expected CAGR of 9.7% from 2025 to 2030.

From the perspective of segment development, domestic enterprises in the surgical suture market continue to fill the gaps in mid-to-high-end sutures, forming a complete product line. The suture market features a wide variety and a vast number of SKUs, with the domestic high-end suture market once being a blank space. Barbed sutures were approved by the FDA in 2004, but the first domestic barbed suture was not approved until 2019. In recent years, the approval of domestic barbed sutures and antibacterial sutures has narrowed the gap with foreign companies. We expect this trend to continue, with domestic brands continuously launching more surgical sutures of different materials and structures. In response to competition, foreign companies are accelerating the introduction of new products to the Chinese market, achieving "zero time difference" in product launches between China and abroad, and promoting the localization of suture production in China.

Based on this, leveraging their complementary strengths, the two parties will achieve a powerful "two-way collaboration" by integrating Hua'an Zhonghui's advantages in sales capabilities, user base, channel networks, and service experience with Boni Medical's innovative expertise in minimally invasive surgical medical device technology.

Nanchang Hua'an Zhonghui Health Technology Co., Ltd., founded in March 2010, specializes in the R&D, production, and sales of domestic high-frequency electrosurgical equipment and single-use consumables, and is a national-level "Little Giant" enterprise specializing in specific sectors with sophisticated technologies to produce novel and unique products. Upholding the cultural philosophy of "Putting the People First, Health as the Foundation," the company has been deeply rooted in the industry for over a decade, consistently adhering to the development path of "specialization, refinement, uniqueness, and novelty." Its products feature a complete range of specifications and innovative design concepts, ranking among the top in sales in the domestic high-frequency electrosurgical medical device market. The company possesses advanced intelligent production and processing equipment, independent intellectual property rights, a stringent quality assurance system, and an excellent management team. Hua'an Zhonghui actively invests in R&D, continuously promotes product innovation, and aims to consistently create value for clinical users and patients, building core product competitiveness. The company has established comprehensive R&D bases in Nanchang, Beijing, and Suzhou, collaborates technically with several national key hospitals and institutions, and holds 75 patent certificates, including 24 invention patents. Its patented products have repeatedly led technological revolutions in the industry.

Boni Medical Technology (Changzhou) Co., Ltd., founded in 2018, is a medical device company focused on the R&D, production, and sales of automated suturing and minimally invasive surgical products. The company's mission is to "Drive Medical Advancement with Technology, Cherish Life and Health with Care, and Create a Better Future for Patients," providing doctors and patients with higher cost-effective products and superior services. In the medical field, we are moving from "Made in China" to "Created in China." To date, the company has obtained over 60 national patents, including 4 invention patents.

Mr. Chen Hua, Chairman of Hua'an Zhonghui, stated: "Boni Medical Technology (Changzhou) Co., Ltd. has left a deep impression on us with its innovative expertise, brand leadership, market expansion, and industry influence in the field of minimally invasive surgical medical device technology. Your company's advanced development philosophy and enterprising spirit are truly admirable."

Mr. Shen Xing, Chairman of Boni Medical, emphasized: "Choosing to cooperate with Hua'an Zhonghui is a crucial step in our corporate strategic transformation. Nanchang Hua'an Zhonghui Health Technology Co., Ltd. possesses a rich product line in high-frequency electrosurgery and has unique resources and advantages in sales capabilities and user base accumulation within the surgical medical device industry. Our shared goal is to build the enterprise into a leader in surgical instruments."

Currently, the domestic medical surgical instrument market is in a period of transformation, with the existing landscape being reshaped. In areas once dominated by foreign companies, such as laparoscopic staplers, ultrasonic scalpels, sutures, and endoscopes, the market share of domestic enterprises is rapidly increasing. At this stage, domestic companies with mature products and stable quality will capture a larger market share. This cooperation represents a deep strategic alliance between the two parties based on the future development of healthcare and will inject new, powerful momentum into the development of the surgical instrument field.

In the future, the two parties will engage in in-depth R&D and integration in areas such as open surgical instruments, minimally invasive surgical instruments, and specialized suture products, jointly building a leading enterprise in surgical instruments, promoting the high-quality development of medical surgical instruments, and ensuring that the fruits of cooperation tangibly benefit a broad range of patients.